• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高剂量泼尼松龙有效治疗Ⅰ型戈谢病的疼痛性骨危象

Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone.

作者信息

Cohen I J, Kornreich L, Mekhmandarov S, Katz K, Zaizov R

机构信息

Schneider Children's Medical Centre of Israel, Petah Tiqva, Israel.

出版信息

Arch Dis Child. 1996 Sep;75(3):218-22. doi: 10.1136/adc.75.3.218.

DOI:10.1136/adc.75.3.218
PMID:8976661
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1511695/
Abstract

In type I Gaucher's disease, episodes of severe disabling bone pain, the so called bone crises, may be resistant to all analgesics, including narcotics. The demonstration of subperiosteal oedema on magnetic resonance imaging (MRI) led to an attempt to use steroids to relieve the oedema and thereby the pain. On eight occasions, five patients with documented bone crises received conventional dose steroids (20 mg/m2/day) with considerable shortening of the attacks. On six occasions five further patients received high dose methylprednisolone (30 mg/kg intravenously or 1 g/m2 orally daily for two days), which was followed by oral prednisone for three to five days on the last four occasions. In this later group, pain relief was evident within several hours. Three treatments were given on an ambulatory basis. The MRI scan of one of these patients showed no subperiosteal fluid collection five days after high dose steroids had been started, and on subsequent x ray examination, there was no periosteal elevation. This treatment should be considered in cases of Gaucher's disease with bone crises.

摘要

在I型戈谢病中,严重致残性骨痛发作,即所谓的骨危象,可能对包括麻醉药在内的所有镇痛药均无反应。磁共振成像(MRI)显示的骨膜下水肿促使人们尝试使用类固醇来减轻水肿,从而缓解疼痛。有8次,5例确诊为骨危象的患者接受了常规剂量的类固醇治疗(20mg/m²/天),发作时间显著缩短。另有6次,5例患者接受了大剂量甲泼尼龙治疗(静脉注射30mg/kg或口服1g/m²,连续两天),后4次在随后的3至5天口服泼尼松。在这组后期患者中,数小时内疼痛即明显缓解。3次治疗是在门诊进行的。其中1例患者在开始使用大剂量类固醇5天后,MRI扫描显示骨膜下无液体积聚,随后的X线检查也未发现骨膜抬高。对于患有骨危象的戈谢病患者,应考虑这种治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bca/1511695/dfa694e1dc3a/archdisch00609-0059-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bca/1511695/03dfcae5eaa6/archdisch00609-0056-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bca/1511695/3313db582be7/archdisch00609-0057-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bca/1511695/2df70b1d894b/archdisch00609-0057-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bca/1511695/797b87c5b14a/archdisch00609-0058-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bca/1511695/dfa694e1dc3a/archdisch00609-0059-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bca/1511695/03dfcae5eaa6/archdisch00609-0056-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bca/1511695/3313db582be7/archdisch00609-0057-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bca/1511695/2df70b1d894b/archdisch00609-0057-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bca/1511695/797b87c5b14a/archdisch00609-0058-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bca/1511695/dfa694e1dc3a/archdisch00609-0059-a.jpg

相似文献

1
Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone.高剂量泼尼松龙有效治疗Ⅰ型戈谢病的疼痛性骨危象
Arch Dis Child. 1996 Sep;75(3):218-22. doi: 10.1136/adc.75.3.218.
2
Hemorrhage associated with "bone crisis" in Gaucher's disease identified by magnetic resonance imaging.通过磁共振成像识别的戈谢病中与“骨危象”相关的出血。
Skeletal Radiol. 1991;20(7):479-82. doi: 10.1007/BF00194240.
3
Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease.评论:低剂量高频酶替代疗法可预防严重青少年型I型戈谢病患者发生骨折,但无法完全抑制疼痛性骨危象。
Blood Cells Mol Dis. 1998 Sep;24(3):303-5; discussion 306-8. doi: 10.1006/bcmd.1998.0196.
4
Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease.氨羟丙叉二膦酸盐(APD)治疗可改善戈谢病的临床骨骼表现。
Pediatrics. 1994 Sep;94(3):385-9.
5
[Bone manifestations of Gaucher's disease in Mexican patients].[墨西哥患者戈谢病的骨骼表现]
Acta Ortop Mex. 2010 Sep-Oct;24(5):351-8.
6
Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.戈谢病的酶替代疗法:加拿大早期经验
CMAJ. 1998 Nov 17;159(10):1273-8.
7
Managing Gaucher.管理戈谢病
Isr Med Assoc J. 2000 Mar;2(3):260.
8
Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate).
Q J Med. 1991 Jun;79(290):503-15.
9
Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter.I型戈谢病成年患者骨骼受累情况的量化:通过狄克逊定量化学位移成像测量脂肪分数作为有效参数。
AJR Am J Roentgenol. 2002 Oct;179(4):961-5. doi: 10.2214/ajr.179.4.1790961.
10
[Bone disease in Gaucher's disease].[戈谢病中的骨病]
Med Clin (Barc). 2011 Sep;137 Suppl 1:23-31. doi: 10.1016/S0025-7753(11)70013-6.

引用本文的文献

1
A Case of Gaucher Disease With Atypical Presentation Mimicking Chronic Recurrent Multifocal Osteomyelitis.一例表现不典型、酷似慢性复发性多灶性骨髓炎的戈谢病病例。
Cureus. 2025 Jan 6;17(1):e77028. doi: 10.7759/cureus.77028. eCollection 2025 Jan.
2
Left to themselves: Time to target chronic pain in childhood rare diseases.留给他们自己:是时候针对儿童罕见病的慢性疼痛进行靶向治疗了。
Neurosci Biobehav Rev. 2021 Jul;126:276-288. doi: 10.1016/j.neubiorev.2021.03.008. Epub 2021 Mar 24.
3
Lysosomal storage disease overview.溶酶体贮积症概述。

本文引用的文献

1
Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months.1型戈谢病的酶替代疗法:33例接受6至24个月治疗患者的剂量疗效及不良反应
Blood. 1993 Jul 15;82(2):408-16.
2
Cardiovascular collapse after high dose methylprednisolone.
Pediatr Hematol Oncol. 1993 Jul-Sep;10(3):v-vii. doi: 10.3109/08880019309029486.
3
High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease.高剂量静脉注射甲泼尼龙治疗镰状细胞病儿童和青少年的疼痛
Ann Transl Med. 2018 Dec;6(24):476. doi: 10.21037/atm.2018.11.39.
4
Gaucher disease.戈谢病
J Clin Exp Hepatol. 2014 Mar;4(1):37-50. doi: 10.1016/j.jceh.2014.02.005. Epub 2014 Apr 21.
5
Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.戈谢病:代谢缺陷、病理生理学、表型及自然史
Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1(0 1):72-81.
6
Revised recommendations for the management of Gaucher disease in children.儿童戈谢病管理的修订建议。
Eur J Pediatr. 2013 Apr;172(4):447-58. doi: 10.1007/s00431-012-1771-z. Epub 2012 Jul 8.
7
Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring.小儿非神经元型戈谢病:治疗与监测建议
Eur J Pediatr. 2004 Feb;163(2):67-75. doi: 10.1007/s00431-003-1363-z. Epub 2003 Dec 16.
8
Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.小儿非神经元型戈谢病:临床表现、诊断与评估。共识声明。
Eur J Pediatr. 2004 Feb;163(2):58-66. doi: 10.1007/s00431-003-1362-0. Epub 2003 Dec 16.
N Engl J Med. 1994 Mar 17;330(11):733-7. doi: 10.1056/NEJM199403173301101.
4
Gaucher disease: a heterogeneous clinical complex for which effective enzyme replacement has come of age.戈谢病:一种临床症状多样的疾病,针对其有效的酶替代疗法已走向成熟。
Am J Med Sci. 1993 May;305(5):331-44. doi: 10.1097/00000441-199305000-00014.
5
Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease.氨羟丙叉二膦酸盐(APD)治疗可改善戈谢病的临床骨骼表现。
Pediatrics. 1994 Sep;94(3):385-9.
6
Selective effects of glucocerebroside (Gaucher's storage material) on macrophage cultures.葡萄糖脑苷脂(戈谢病储存物质)对巨噬细胞培养物的选择性作用。
J Clin Invest. 1981 Nov;68(5):1182-9. doi: 10.1172/jci110363.
7
Aseptic osteomyelitis in Gaucher's disease.
Isr J Med Sci. 1965 Jul;1(4):531-6.
8
Bone changes in chronic adult Gaucher's disease.成人慢性戈谢病的骨骼改变
Am J Roentgenol Radium Ther Nucl Med. 1970 Dec;110(4):800-7. doi: 10.2214/ajr.110.4.800.
9
Bone crises and chronic osteomyelitis in Gaucher's disease.
Clin Orthop Relat Res. 1971 Sep;79:132-40. doi: 10.1097/00003086-197109000-00020.
10
Gaucher disease: assessment with MR imaging.
Radiology. 1986 Oct;161(1):239-44. doi: 10.1148/radiology.161.1.3763873.